Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Bempedoic acid in real-world clinical practice: baseline and 8-week data from the Italian prospective, non-interventional MILOS study].

Giornale italiano di cardiologia (2006)·2026

Same author

Evolocumab in Patients With High-Risk Diabetes: Results From the VESALIUS-CV Trial.

Diabetes care·2026

Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026

Same author

From static lipids to dynamic risk: The role of atherogenic index of plasma in prediabetes.

Journal of diabetes and its complications·2026

Same author

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Circulation·2026

Same author

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.

JAMA·2026

Same journal

Mast Cells and Cardiovascular Disorders.

Current vascular pharmacology·2026

Same journal

Occupational and Environment-Related Cardiovascular Disease: A Comprehensive Review of the Literature.

Current vascular pharmacology·2026

Same journal

Metalloproteinases 2 and 9 as Biomarkers in Acute Elevation of Blood Pressure.

Current vascular pharmacology·2026

Same journal

Is the Cardiovascular Risk Increased in Patients with Isolated Systolic Hypertension and Anemia?

Current vascular pharmacology·2026

Same journal

Periodontal Disease and Cardiovascular Risk Factors.

Current vascular pharmacology·2026

Same journal

The Use of Colchicine in Cardiovascular Disease: Anti-Inflammatory Mechanisms and Clinical Utility.

Current vascular pharmacology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Lipoprotein(a): current perspectives.

Ioanna Gouni-Berthold¹, Heiner K Berthold

¹University of Cologne, Center of Endocrinology, Diabetes and Preventive Medicine, Cologne, Germany. ioanna.berthold@uni-koeln.de

Current Vascular Pharmacology

|May 3, 2011

Summary

This summary is machine-generated.

Elevated lipoprotein(a) [Lp(a)] is causally linked to atherosclerosis and cardiovascular disease, independent of cholesterol levels. Current therapies offer moderate Lp(a) reduction without proven cardiovascular benefit.

Related Experiment Videos

Last Updated: Jun 2, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Area of Science:

Cardiovascular Medicine
Genetics
Epidemiology

Background:

Elevated lipoprotein(a) [Lp(a)] concentrations are strongly associated with atherosclerosis and cardiovascular disease.
This association is continuous, lacks a threshold, and is independent of LDL-C and HDL-C levels.

Purpose of the Study:

To review evidence linking Lp(a) to atherosclerotic disease.
To discuss potential pro-atherosclerotic mechanisms of Lp(a).
To evaluate therapeutic options for reducing elevated Lp(a).

Main Methods:

Review of genetic and epidemiological studies.
Analysis of proposed pathophysiological mechanisms.
Evaluation of existing therapeutic strategies.

Main Results:

Lp(a) promotes atherosclerosis through mechanisms like cholesterol entrapment, inflammation, oxidized phospholipids, impaired fibrinolysis, and enhanced coagulation.
Two phenotypes exist: isolated hyperlipoproteinemia(a) and combined elevations with LDL-C.
No selective Lp(a)-lowering drugs are available; current therapies have moderate effects and may lower LDL-C.

Conclusions:

High-dose niacin shows the strongest Lp(a)-lowering effect but lacks convincing evidence for cardiovascular benefit in isolated Lp(a) elevations.
Further research is needed to understand Lp(a) mechanisms and develop effective, targeted therapies.